Published in Vaccine Weekly, October 13th, 2010
On December 16, 2009, NanoBio announced an exclusive licensing agreement in the U.S. and Canada with GSK for the over-the-counter use of NB-001, a novel compound in development as an advanced treatment for cold sores. NB-001 provides significant antimicrobial activity against the virus that causes cold sores, herpes labialis. The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly